Diag-Nose.io, a Seattle, WA-based respiratory healthcare company, raised $2M in Seed funding.
The round was led by Breakthrough Victoria, with participation from Radar Ventures, a syndicate of physicians from Specialty Physician Associates (SPA), biotech angel investors Carl Stubbings, Stephen Ho, and Richard Lipscombe, as well as physicians affiliated with leading U.S. hospitals. Carl Stubbings will join Diag-Nose.io’s board as Chairperson.
The company intends to use the funds to expand operations and its R&D efforts.
Founded in 2020 and led by CEO Eldin Rostom, Diag-Nose.io is a biotechnology company focused on translating the complexities of the unified airway into precision diagnostic and drug discovery solutions. Its RhinoMAP™ platform combines machine learning (artificial intelligence) with advanced proteomics to enable precision-matched treatments based on each patient’s unique biological profile, or “endotype.”
The system leverages patented nasal liquid biopsy technology, the ABEL Microsampler™, to collect nasal fluid samples for comprehensive biomarker analysis. These insights intend to guide care by identifying disease progression, therapeutic responsiveness, and optimal treatment pathways.
